Panacea Biotec, a leading biotechnology company in India, has announced the launch of the world’s first fully liquid wP-IPV-based Pentavalent vaccine, “EasyFourPol®,” in India. This vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections from Haemophilus Influenza Type b.
EasyFourPol® is a ready-to-use combination vaccine that eliminates the need for on-site preparation by healthcare workers, offering the same level of protection as single-antigen vaccines. It also reduces the number of injections required for immunization, thereby minimizing the pain and discomfort for children.
Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec, expressed delight in launching EasyFourPol®, emphasizing its innovative approach in simplifying vaccinations. He said that the vaccine aligns with UN Sustainable Development Goals, particularly in reducing the under-five mortality rate.
A New Milestone in Transplant Care
In addition to the launch of EasyFourPol®, Panacea Biotec’s subsidiary, Panacea Biotec Germany GmbH, has successfully registered Valganciclovir 50 mg/ml Powder for Oral Solution in Germany. This medication is a cytomegalovirus (CMV) DNA polymerase inhibitor, which is used for the treatment and prevention of CMV infections in transplant recipients.
CMV is a common virus that can cause serious complications in people with weakened immune systems, such as organ transplant recipients. Valganciclovir Powder for Oral Solution is a generic version of Valcyte®, which is marketed by Roche. Panacea Biotec is the first company to launch this product in Germany, competing in a €1 million market.
Dr. Jain underscored the significance of expanding their therapy focus, expressing enthusiasm for the addition of Valganciclovir Powder for Oral Solution to their transplant portfolio in Germany. He said that the company remains dedicated to scaling operations and building trust with healthcare practitioners as a reliable supplier of high-quality medicines for transplant care.
A Vision for the Future
Panacea Biotec is not only focused on the present, but also on the future. The company is developing a vaccine platform that can address pandemic outbreaks of betacoronaviruses, such as SARS, MERS, and Covid-19. This is a collaborative effort of Panacea Biotec, Government of India (Translational Health Science and Technology Institute [THSTI], Faridabad) and Coalition for Epidemic Preparedness Innovations (CEPI).
The company is also developing a first-of-its-kind vaccine for Dengue, a mosquito-borne disease that affects millions of people every year. The vaccine candidate, undergoing clinical trials now, promises protection against all four serotypes of the Dengue virus. The company expects this vaccine to be in the market in the next 2-3 years.
Panacea Biotec is an innovation-driven company that aims to provide high-quality, affordable, and accessible healthcare solutions to the world. With its diversified portfolio of products and services, the company is making a difference in the lives of millions of people.
